Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.
An economic sub-study was run alongside a large multi-centre randomised trial (MRC-CR06) comparing three chemotherapy regimens; de Gramont, Lokich and raltitrexed in patients with metastatic colorectal cancer. Patients in six of 45 centres in the main trial were approached to take part in the sub-st...
Үндсэн зохиолчид: | Hale, J, Cohen, DR, Maughan, T, Stephens, R |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
2002
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
-н: Maughan, T, зэрэг
Хэвлэсэн: (2002) -
Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
-н: Moe, M, зэрэг
Хэвлэсэн: (2008) -
Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
-н: Maughan, T, зэрэг
Хэвлэсэн: (2010) -
A cost comparison of biologic treatment regimens for metastatic colorectal cancer in Italy
-н: Sergio Iannazzo, зэрэг
Хэвлэсэн: (2017-10-01) -
Combination chemotherapy for metastatic colorectal cancer
-н: Koehne Claus-Henning
Хэвлэсэн: (2003-01-01)